维多利亚老品牌76696vic-在线入口

Be the most trusted biotech company

2023-06-26

Henlius Immune Checkpoints Inhibitor Anti-CTLA-4 mAb Received IND Approval for the Treatment of HCC
2023-06-15

First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients
2023-06-12

Henlius Shines for Five Consecutive Years at BIO International Convention
2023-06-06

Results From the Phase 2 Clinical Trial of HLX07 for the Treatment of ESCC Released at 2023 ASCO
2023-06-06

Results From the Phase 2 Clinical Trial of Henlius BRAFV600E Inhibitor HLX208 for the Treatment of LCH and/or ECD Released at 2023 ASCO Annual Meeting
2023-05-26

2023 ASCO Annual Meeting Released Clinical Data of Two Henlius Trials
2023-05-26

Results from the Phase 3 Clinical Study of Novel Anti-PD-1 mAb Serplulimab for the First-line Treatment of ESCC Released at 2023 ASCO Annual Meeting
2023-05-19

Henlius Will Be at BIO 2023
2023-05-17

Phase I Clinical Results of Henlius HLX22, an innovative anti-HER2 mAb, Published in Investigational New Drugs